{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=11&q=hormone-sensitive",
    "query": {
      "q": "hormone-sensitive",
      "condition": "Prostate Cancer",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 159,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=12&q=hormone-sensitive&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=10&q=hormone-sensitive&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T18:35:32.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07672119",
      "title": "A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "55 Years and older · Male only"
      },
      "enrollment_count": 3000,
      "start_date": "2026-06-04",
      "completion_date": "2027-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07672119"
    },
    {
      "nct_id": "NCT03689699",
      "title": "Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Adenocarcinoma of the Prostate"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "BMS-986253",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Stein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 59,
      "start_date": "2018-10-11",
      "completion_date": "2024-05-02",
      "has_results": true,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03689699"
    },
    {
      "nct_id": "NCT01666314",
      "title": "Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Orteronel",
          "type": "DRUG"
        },
        {
          "name": "Orteronel Placebo",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 137,
      "start_date": "2012-08-20",
      "completion_date": "2016-09-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-20",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666314"
    },
    {
      "nct_id": "NCT04729114",
      "title": "A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Metastatic Castration-sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PRL-02 injection",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 174,
      "start_date": "2021-06-14",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04729114"
    },
    {
      "nct_id": "NCT07824349",
      "title": "JUR-003 in Adult Patients With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer",
        "Oligometastatic Prostate Cancer (OMPC)",
        "Metastatic Hormone Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "JUR-003",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Juri Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 210,
      "start_date": "2026-09",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 4,
      "location_summary": "Grand Rapids, Michigan • Lake Success, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07824349"
    },
    {
      "nct_id": "NCT01516866",
      "title": "Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 58,
      "start_date": "2011-11",
      "completion_date": "2018-01-01",
      "has_results": false,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • New York, New York • Madison, Wisconsin",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01516866"
    },
    {
      "nct_id": "NCT03533946",
      "title": "Rucaparib in Nonmetastatic prOstAte With BRCAness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2019-05-20",
      "completion_date": "2023-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03533946"
    },
    {
      "nct_id": "NCT07216248",
      "title": "Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"
      ],
      "interventions": [
        {
          "name": "relugolix + ARPI.",
          "type": "DRUG"
        },
        {
          "name": "Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI",
          "type": "DRUG"
        },
        {
          "name": "relugolix or androgen deprivation therapy (ADT) + ARPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 160,
      "start_date": "2025-10-27",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07216248"
    },
    {
      "nct_id": "NCT00035997",
      "title": "Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Zometa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 261,
      "start_date": "2002-04",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2009-11-23",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035997"
    },
    {
      "nct_id": "NCT05884398",
      "title": "A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castrate-sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Androgen-deprivation Therapy (ADT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 420,
      "start_date": "2023-08-31",
      "completion_date": "2028-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-15T18:35:32.503Z",
      "location_count": 46,
      "location_summary": "Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05884398"
    }
  ]
}